Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis

被引:0
作者
Yan Ma
Michael Baltezor
Lian Rajewski
Jennifer Crow
Glenson Samuel
Vincent S. Staggs
Katherine M. Chastain
Jeffrey A. Toretsky
Scott J. Weir
Andrew K. Godwin
机构
[1] University of Kansas Medical Center,Department of Pathology and Laboratory Medicine
[2] University of Kansas Cancer Center,Lead Development Optimization Shared Resource
[3] Biotechnology Innovation and Optimization Center,Institute for Advancing Medical Innovation
[4] University of Kansas Medical Center,Division of Hematology/Oncology
[5] Children’s Mercy Kansas City,Health Services & Outcomes Research, Children’s Mercy Kansas City and School of Medicine
[6] University of Missouri-Kansas City,Department of Oncology
[7] Georgetown University Medical Center,Department of Pharmacology, Toxicology and Therapeutics
[8] University of Kansas Medical Center,University of Kansas Cancer Center
[9] University of Kansas Medical Center,undefined
来源
Journal of Molecular Medicine | 2019年 / 97卷
关键词
Ewing sarcoma; Entinostat; Histone deacetylase inhibitor; EWS-FLI1; HDAC3;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:957 / 972
页数:15
相关论文
共 405 条
[1]  
Balamuth NJ(2010)Ewing’s sarcoma Lancet Oncol 11 184-192
[2]  
Womer RB(2010)Chemotherapy in Ewing’s sarcoma Indian J Orthop 44 369-377
[3]  
Jain S(2014)Outcome for children with metastatic solid tumors over the last four decades PLoS One 9 4148-4154
[4]  
Kapoor G(2012)Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group J Clin Oncol 30 423-428
[5]  
Perkins SM(2017)Long-term outcomes and complications in pediatric Ewing sarcoma Am J Clin Oncol 40 5752-5756
[6]  
Shinohara ET(1993)Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation Proc Natl Acad Sci U S A 90 5747-5754
[7]  
DeWees T(2001)Biology of EWS/ETS fusions in Ewing’s family tumors Oncogene 20 324-327
[8]  
Frangoul H(2009)Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children’s Oncology Group Pediatr Blood Cancer 52 579-585
[9]  
Womer RB(2012)A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children’s Oncology Group Eur J Cancer 48 440-444
[10]  
West DC(2015)Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children’s Oncology Group Pediatr Blood Cancer 62 158-159